Patents by Inventor Hans-Jorg Buhring
Hans-Jorg Buhring has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9580686Abstract: The present invention relates to the use of at least one antibody which binds to the SUSD2 antigen, or to functional fragments of the antibody, in combination with at least one of the following: an antibody which binds to CD140b, an antibody which binds to CD56, and/or an antibody which binds to TNAP, or functional fragments thereof, for isolation of mesenchymal stem cells, especially those having particularly chondrocytic and osteogenic differentiation potential. The invention further relates to processes for isolating such stem cells using these antibodies.Type: GrantFiled: September 22, 2014Date of Patent: February 28, 2017Assignee: Eberhard-Karls-Universitaet Tuebingen UniversitaetsklinikumInventors: Hans-Jorg Buhring, Sabrina Grimm, Flavianna Cerabona
-
Publication number: 20150010516Abstract: The present invention relates to the use of at least one antibody which binds to the SUSD2 antigen, or to functional fragments of the antibody, in combination with at least one of the following: an antibody which binds to CD140b, an antibody which binds to CD56, and/or an antibody which binds to TNAP, or functional fragments thereof, for isolation of mesenchymal stem cells, especially those having particularly chondrocytic and osteogenic differentiation potential.Type: ApplicationFiled: September 22, 2014Publication date: January 8, 2015Inventors: Hans-Jorg Buhring, Sabrina Grimm, Flavianna Cerabona
-
Publication number: 20130130315Abstract: An isolated nucleic acid molecule selected from the group consisting of: vi. a nucleic acid molecule comprising a nucleotide sequence which is at least 85% identical to the nucleotide sequence of SEQ ID NO:1 or a complement thereof; vii. a nucleic acid molecule comprising a fragment of at least 1500 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof; viii. a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO:2; ix. a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 500 contiguous amino acids of SEQ ID NO: 2; and x.Type: ApplicationFiled: April 6, 2011Publication date: May 23, 2013Applicant: ADVANCECOR GMBHInventors: Meinrad Gawaz, Tanja Schönberger, Heidrun Degen, Götz Münch, Hans-Peter Holthoff, Andreas Bültmann, Hans-Jörg Bühring, Christoph Leder
-
Patent number: 8163495Abstract: The present invention concerns antibodies produced from hybridoma cell lines chosen from the group comprising W8B2, W1C3, W7C6, W5C4, 24D2, 28D4, HEK-3D6, W4A5, W3D5, W5C5, 9A3G9, 58B1, F9-3C2F1, 39D5, for isolating and/or identifying homogenous mesenchymal stem cells. Furthermore a method is presented with which mesenchymal stem cells from adult primary tissue, for example bone marrow, can be identified and isolated with a high level of purity.Type: GrantFiled: September 11, 2007Date of Patent: April 24, 2012Assignee: Eberhard-Karls-Universität Tuebingen UniversitaetsklinikumInventors: Hans-Jorg Buhring, Reiner Lammers, Sabrina Treml, Venkata Lokesh Battula
-
Publication number: 20100068145Abstract: The present invention relates to a bispecific fusion protein, comprising (a) a first polypeptide which binds to collagen, and (b) a second polypeptide which binds to endothelial precursor cells. Also, pharmaceutical compositions are disclosed, comprising the fusion protein of the invention, as well as methods for using the fusion protein, in particular for treating or preventing lesions of vessels and tissues.Type: ApplicationFiled: August 20, 2009Publication date: March 18, 2010Applicant: Eberhard-Karls-Universitaet TuebingenInventors: Harald Langer, Meinrad Gawaz, Hans-Jorg Buhring, Thomas Skutella, Gundram Jung
-
Publication number: 20080267955Abstract: The present invention relates to a method for treating and a method for identifying a tumor of a human or animal comprising administering composition comprising an agent which binds to Frizzled 9.Type: ApplicationFiled: January 24, 2008Publication date: October 30, 2008Applicant: Eberhard-Karls-Universitaet Tuebingen UniversitaetsklinikumInventors: Hermann Schluesener, Hans-Jorg Buhring, Sigrid Hojak, Ingrid Albert
-
Patent number: 7364863Abstract: The invention relates to a monoclonal antibody, or fragments thereof, for isolating and/or identifying mesenchymal stem cells. In this connection, the antibody, or fragments thereof, bind to an antigen which is the same as that bound to by an antibody which is produced by the hybridoma cell line W8B2, which was deposited on 14.08.2002 in the DSMZ [German collection of microorganisms and cell cultures] under the number DSM ACC2567.Type: GrantFiled: March 9, 2005Date of Patent: April 29, 2008Assignee: Eberhard-Karls-Universitaet Tuebingen UniversitaetsklinikumInventors: Hans-Jorg Buhring, Reiner Lammers, Wichard Vogel
-
Publication number: 20080075699Abstract: The present invention concerns antibodies produced from hybridoma cell lines chosen from the group comprising W8B2, W1C3, W7C6, W5C4, 24D2, 28D4, HEK-3D6, W4A5, W3D5, W5C5, 9A3G9, 58B1, F9-3C2F1, 39D5, for isolating and/or identifying homogenous mesenchymal stem cells. Furthermore a method is presented with which mesenchymal stem cells from adult primary tissue, for example bone marrow, can be identified and isolated with a high level of purity.Type: ApplicationFiled: September 11, 2007Publication date: March 27, 2008Applicant: Eberhard-Karls-Universitat Tuebingen UniversitaetsklinikumInventors: Hans-Jorg Buhring, Reiner Lammers, Sabrina Treml, Venkata Battula
-
Patent number: 6949346Abstract: The present invention relates to an antibody for the detection quantification, or isolation of basophils, mast cells, the precursor cells of basophils or mast cells, or a surface structure of basophils or mast cells. This antibody corresponds to an antibody with the designation 97A6, produced and released by hybridoma cells that were deposited in accordance with the Budapest Treaty on Feb. 12, 1997 under accession number DSM ACC 2297 at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ).Type: GrantFiled: November 16, 2001Date of Patent: September 27, 2005Assignee: Eberhard-Karls-Universität Tübingen UniversitaäsklinikumInventors: Hans-Jorg Buhring, Johannes Andreas Van Agthoven, David Jarossay
-
Patent number: 6913894Abstract: Monoclonal antibodies which bind specifically to the extracellular domain of the SIRP cell surface glycoproteins, and which, in some cases, block the interaction of SIRP with the surface molecule CD47, are described.Type: GrantFiled: May 29, 2002Date of Patent: July 5, 2005Assignee: Eberhard-Karls-Universitat Tubingen UniversitatsklinikumInventors: Hans-Jörg Bühring, Axel Ullrich, Zhengjun Chen, Charles Cant
-
Publication number: 20030054415Abstract: Monoclonal antibodies which bind specifically to the extracellular domain of the SIRP cell surface glycoproteins, and which, in some cases, block the interaction of SIRP with the surface molecule CD47, are described.Type: ApplicationFiled: May 29, 2002Publication date: March 20, 2003Inventors: Hans-Jorg Buhring, Axel Ullrich, Zhengjun Chen, Charles Cant
-
Publication number: 20020160429Abstract: The present invention concerns an antibody for the detection and/or quantification and/or isolation of basophils and/or mast cells and/or of the precursor cells of basophils and/or mast cells and/or of a surface structure of said cells, binding of the antibody occurring to that surface structure of the cells to which can bind the antibody with the designation 97A6, produced and released by hybridoma cells that were deposited in accordance with the Budapest Treaty on Feb. 12, 1997 under number DSM ACC 2297 at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ).Type: ApplicationFiled: November 16, 2001Publication date: October 31, 2002Inventors: Hans-Jorg Buhring, Johannes Andreas Van Agthoven, David Jarossay
-
Patent number: 6323321Abstract: The present invention relates to a monoclonal antibody binding an antigen on the megakaryocytic cell line UT-7. The invention further relates to hybridoma cells producing such an antibody.Type: GrantFiled: June 30, 1999Date of Patent: November 27, 2001Assignee: Eberhard-Karls-Universitat Tubingen UniversitatsklinikumInventor: Hans-Jörg Bühring
-
Patent number: 6156882Abstract: The invention relates to a monoclonal antibody specifically binding to the human FLT3/FLK2 receptor protein. The invention further relates to hybridoma cells producing such an antibody, as well as to a method for generation of such hybridoma cells. The monoclonal antibody is the antibody produced and released by hybridoma cells deposited under No. DSM 2249 at the German Collection of Microorganisms and Cell Cultures (DSMZ) and designated as 4G8B4B12.Type: GrantFiled: June 26, 1998Date of Patent: December 5, 2000Assignee: Eberhard-Karls-Universitat TubingenInventors: Hans-Jorg Buhring, Irene Rappold
-
Patent number: 6143296Abstract: A monoclonal antibody specific to the cell surface glycoprotein CD164 is designated 67D2 and produced by hybridoma cells deposited under No. DSM ACC2303 at the German Collection of Microorganisms and Cell Cultures Ltd., DSMZ.Type: GrantFiled: June 26, 1998Date of Patent: November 7, 2000Assignee: Eberhard-Karls-Universitat TubingerInventors: Hans-Jorg Buhring, Suzanne M. Watt
-
Patent number: 6024964Abstract: According to certain embodiments, the invention relates to a method of producing antibodies employing an immunoconjugate produced by conjugating at least one membrane-anchoring compound with at least one partial sequence of a viral, bacterial, or protoral protein. The immunoconjugate has the advantage that it can be stored for a very long time even without cooling. According to certain embodiments, the invention relates to an immunoconjugate for the specific induction of cytotoxic T-lymphocytes which comprises a conjugate from at least one membrane anchor compound and a protein, containing at least one killer T-cell epitope, of a virus, a bacterium, a parasite or a tumor antigen, or at least one partial sequence containing at least one killer T-cell epitope of a viral, bacterial or parasite protein or of a tumor antigen.Type: GrantFiled: June 6, 1995Date of Patent: February 15, 2000Assignee: Hoechst AktiengesellschaftInventors: Gunther Jung, Karl-Heinz Wiesmuller, Jorg Metzger, Hans-Jorg Buhring, Gerhard Becker, Wolfgang Bessler
-
Patent number: 5808002Abstract: The present invention relates to a monoclonal antibody that binds specifically to a human stem cell factor (SCF) receptor. The invention further relates to hybridoma cells that produce such an antibody, and to a method for generating such hybridoma cells.Type: GrantFiled: January 3, 1997Date of Patent: September 15, 1998Assignee: Eberhard-Karls-Universitat TubingenInventor: Hans-Jorg Buhring
-
Patent number: 5777084Abstract: The invention relates to a monoclonal antibody specifically binding to the human FLT3/FLK2 receptor protein. The invention further relates to hybridoma cells producing such an antibody, as well as to a method for generation of such hybridoma cells. One example of such a monoclonal antibody is the antibody produced and released by hybridoma cells deposited under No. DSM 2248 at the German Collection of Microorganisms and Cell Cultures (DSMZ).Type: GrantFiled: January 31, 1997Date of Patent: July 7, 1998Assignee: Eberhard-Karls-Universitat TubingenInventor: Hans-Jorg Buhring
-
Patent number: 5763274Abstract: An antibody against peanut agglutinin-(PNA)-binding glycoprotein on the surface of cells is named 103B2 and registered at the German Collection of Microorganisms and Cell Cultures GmbH, DSMZ, under the Budapest Treaty.Type: GrantFiled: August 16, 1996Date of Patent: June 9, 1998Assignee: Eberhard-Karls-Universitat TubingenInventors: Hans-Jorg Buhring, Andrew Zannettino, Paul J. Simmons